Table 1.

Demographic and clinical characteristics of patients

	Responders	Non-responders	All
Total	34	30	64
Mean age (years)	58 (range, 35–75)	54.53 (range, 27–73)	56.33 (range, 27–75)
Woman/man	28/6	26/4	54/10
MTX and adalimumab	9	13	22
MTX and etanercept	5	2	7
MTX and infliximab	5	4	9
Adalimumab	8	10	18
Etanercept	7	1	8
Infliximab	0	0	0
Mean pre-DAS28 score	6.21 (range, 4.08–8.96)	5.43 (range, 3.75–7.38)	5.85 (range, 3.75–8.96)
Mean post-DAS28 score	3.64 (range, 1.18–6.15)	5.61 (range, 3.49–7.27)	4.53 (range, 1.18–7.27)